Loading
Inhaltsverzeichnis

Afatinib (Giotrif®)

Dokument Factsheet
Spezifizierung Lungenkarzinom, kleinzellig (SCLC)
Stand April 2020
Dies ist die aktuell gültige Version des Dokuments

1Afatinib, NSCLC, EGFRmut

1 N - number of patients2 RR - remission rate, in %3 PFS - progression-free survival in months5 OS - overall survival in months7 SAE - serious adverse events, CTCAE grade 3/48 results for control, results for new therapy9 hazard ratio for new therapy10 n. s. not significant19 CT - chemotherapy

Kommentare